LinkedIn post by Michael Snyder · Feb 2026
Hiring post from scientific co-founder Michael Snyder describing Quinn's use in pharma decisions and the need for additional computational biology talent.
Building Quinn, an AI scientist accelerating pharma/biotech R&D
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
iollo is a Stanford-founded, Y Combinator-backed biotech/healthtech company that started with at-home metabolomics testing for wellness and longevity and now also sells Quinn, an enterprise AI scientist for biopharma R&D.
Primary product
At-home metabolomics blood test with AI-generated wellness reports and coaching
Founded
2022
Headquarters
2261 Market Street #4822, San Francisco, CA 04114, United States
Team size
1-10
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
Metabolomics / healthtech diagnostics / AI for biopharma R&D
Offices
2261 Market Street #4822, San Francisco, CA 04114, United States
Business model
consumer subscription
enterprise SaaS
white-glove services
Funding
Stage
Seed
Total raised
$500K
Latest round
Convertible Note · Sep 2022
Latest amount
$500K
Sep 2022 · Y Combinator
Jul 2022
People & investors
Leadership
Founder and CEO
Co-founder, CPO
Scientific co-founder
Medical Advisory Member
Director of Partnerships
Founders
Co-founder
Work & culture
Science-led and research-heavy, with Stanford/Cornell roots, a publication-oriented team, and a strong emphasis on transparent reasoning, clinical rigor, and personalized health outcomes.
Work style
Flexible
Visa sponsorship
Limited
Compensation
Public job listings suggest a founding AI-scientist role in the roughly $130K-$210K base salary range plus meaningful equity; broader company-wide comp policy is not publicly stated.
Benefits
competitive compensation
meaningful equity
Product & market
Pricing
Consumer subscription tiers priced at $299, $399, and $459 per test; enterprise Quinn appears demo/sales-led rather than publicly priced.
Differentiators
- —600+ metabolite / biomarker panel from a single at-home blood sample
- —AI-generated personalized dietary, behavioral, and therapeutic recommendations
- —longitudinal tracking instead of one-off snapshots
- —enterprise Quinn product runs in the customer's environment with traceable reasoning
- —SOC 2 Type II / HIPAA positioning for enterprise and consumer offerings
Technology
mass spectrometry
AI / machine learning
Python
React
Vercel
MongoDB
PostgreSQL
Redis
AWS Lambda
AWS SQS
Terraform
TypeScript
Tailwind CSS
microservices
ramp
metabolomics
Customers
health-conscious consumers
longevity physicians
medical practices
pharma companies
biotech companies
research institutions
academia
Competitors
Oura
Masimo
Sibel Health
iHealth Labs
Edwards Lifesciences
BioIntelliSense
Endotronix
LongitudeDx
Scale & contact
Estimated revenue
Approx. $440K-$750K estimated ARR (public estimates conflict)
Latest news
LinkedIn post by Ian Boyd · Jul 2025
Company hiring post describing Quinn as an AI scientist already helping pharma partners and highlighting iollo's expansion of its enterprise team.
Mendelspod · Feb 2025
Interview-style piece about iollo's newer enterprise product Quinn and CEO Daniel Gomari, emphasizing pharma R&D decision-making in days rather than months.
Signature Healthcare · Jun 2024
Patient-facing article explaining iollo's at-home metabolomics test, 600+ biomarkers, and how it is used to assess biological age and lifestyle interventions.
iollo blog · Mar 2024
Official educational article on the company's metabolomic testing, its interpretation, and wellness-oriented intervention use cases.
Jobs and careers at iollo
0 jobs at iollo
No open positions
Check back later for new openings